Tirzepatide Benefits and Guidelines for Type 2 Diabetes Management

Primary Glycemic and Weight Loss Benefits

• The American Diabetes Association recommends tirzepatide as a preferred agent for early use in type 2 diabetes with cardiovascular disease risk factors and/or obesity, given its dual benefits on glycemic control and weight management 3, 4
• Tirzepatide reduces hepatic steatosis, benefiting patients with metabolic dysfunction-associated steatotic liver disease 1

Cardiovascular and Cardiometabolic Benefits

• Reduces hepatic steatosis, benefiting patients with metabolic dysfunction-associated steatotic liver disease 1

Hypoglycemia Risk Profile and Safety

• Tirzepatide carries a low risk of hypoglycemia when used appropriately, with a lower risk of hypoglycemia compared to insulin and sulfonylureas 2, 5
• Important perioperative consideration: Delays gastric emptying, which may increase aspiration risk during anesthesia 3, 4

Clinical Pitfalls and Caveats

• May increase risk for malnutrition and sarcopenia with significant weight loss; encourage resistance training and adequate protein intake 6
• Screen patients experiencing rapid weight loss (>4 kg/month) or significant weight loss (>20%) for complications 6